Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 17.24%, which has investors questioning if this is right time to buy.

R&D event highlighted positive ACR-368 endometrial cancer data in OncoSignature-positive (BM+) patients with heavily ...

Acrivon Therapeutics Inc. provided updated phase II data for checkpoint kinase candidate ACR-368, highlighting promising response rates for biomarker-positive patients with endometrial cancer and ...

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by ...

Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the publication of ...

Theratechnologies Inc.’s THTX share price has surged by 20.78%, which has investors questioning if this is right time to sell ...

Imunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.

Endometriosis affects millions worldwide, and March is a critical time to highlight this often-misunderstood condition.

A: About 10% of women in the U.S. are affected by endometriosis, a condition that causes severe period pain. There is no easy blood test to diagnose it. Because of this, and poor awareness and stigma, ...

Subhead: James Van Der Beek shared an update on his battle with stage 3 colorectal cancer shortly after appearing as the ...

Hutchmed (HCM) stock rises despite a 2024 revenue miss as a cancer drug combo it developed with Innovent Biologics (IVBYI) succeeds in a Phase 2/3 trial. Read more here.